Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Panels Favor Advair, Symbicort Over Single-Entity LABAs For Asthma

Executive Summary

Three FDA advisory committees recommended the withdrawal of asthma indications for two long-acting beta agonists - GlaxoSmithKline's Serevent (salmeterol) and Novartis's Foradil (formoterol) -during a Dec. 11 meeting

Related Content

Foradil Completes LABAs’ Exit From Risk Evaluation and Mitigation Strategies
Patient Voice Missing In Asthma Drug Safety Debate – FDA’s Jenkins
AstraZeneca’s Symbicort On Advair’s Heels With COPD Approval
AstraZeneca’s Symbicort On Advair’s Heels With COPD Approval
Biopharma in 2008: What a Difference an Economic Crisis Makes
Death Vs. Symptomatic Relief – Weighing Risks And Benefits For Asthma Drugs
New Foradil Inhaler Falls Prey To Concerns About Single-Entity LABA Products
AstraZeneca Submits Symbicort For Asthmatics As Young As Six
FDA To Conduct Pediatric Safety Analysis for Serevent, Other LABAs
Long-Acting Beta Agonists Revised Labeling Warns Of Asthma Death Potential



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts